,8-lactamase (1, 8) . It was noted to be more active than a variety of other antimicrobial agents in vitro on a per-weight basis (8) . The minimum inhibitory concentration of cefotaxime remained the same (c0.004 jLg/ml) whether 8-lactamase was produced or not (1) . The mean peak serum concentration of cefotaxime after a 1.0-g intramuscular (i.m.) injection has been reported to be 20.5 jug/ml, with a half-life of 1.34 h (4) .
Recently, in a noncomparative clinical trial in Europe, cefotaxime was found to be highly effective against gonococcal urethritis and cervicitis (5 
RESULTS
A total of 126 patients were enrolled in the study. Sixteen patients with sterile pretreatment cultures and 13 patients who did not return for follow-up were excluded. Of the remaining 97 patients, 45 males and 5 females were in the cefotaxime group and 39 males and 8 females were in the penicillin group. Age, race, and duration of symptoms in the two groups were similar. The total number of infected sites was 118.
Results of the two treatment groups are summarized in Table 1 . Cure rates in both groups at all infected sites were 100%.
Two men who received cefotaxime continued to have a discharge at the follow-up visit. Gram stain was negative for gonococci, and cultures were also negative. The patients were treated for postgonococcal urethritis.
No adverse side effects were noted in either treatment group. Cefotaxime administered as a single i.m. injection was better accepted by patients and easier to administer than penicillin, which was administered in two i.m. injections. Cefotaxime was injected without lidocaine. Grading of pain at the injection site in 50 patients treated with cefotaxime and 47 patients treated with penicillin was as follows: cefotaxime-no pain, 20; mild pain, 27; and moderate pain, 3; penicillin-no pain, 14; mild pain, 26; and moderate pain, 7. No significant changes in the pre-and posttreatment laboratory tests were noted in either treatment group.
The minimum inhibitory concentrations of cefotaxime and penicillin were determined for 131 N. gonorrhoeae isolates from this study population. Ninety-five percent of clinical iso- (Fig. 1) . No /8-lactamase-positive N. gonorrhoeae strains were noted in this study. DISCUSSION For over 30 years, penicillin has been one of the primary antimicrobial agents used in the single-dose treatment of gonorrhea. During this period the susceptibility of gonococci to penicillin has decreased (7). Presently, the treatment of gonorrhea with penicillin includes two i.m. injections (2.4 x 106 U each) plus 1 g of oral probenecid. Any further increase in the dose of penicillin would require administration of three i.m. injections, which would make penicillin treatment undesirable for many patients. Furthermore, standard high-dose penicillin therapy does not eradicate infection due to /3-lactamasepositive N. gonorrhoeae (3) . This has prompted a search for new antimicrobial agents for the single-dose treatment of gonorrhea.
Several In this study, cefotaxime was as effective as procaine penicillin in the treatment of uncomplicated gonorrhea. All infected sites were uniformly cured in both treatment groups. However, when compared with gonococcal urethritis, only a small number of cervical, rectal, and pharyngeal gonococcal infections have been treated. Further clinical trials are needed to verify the efficacy of cefotaxirne against infections of these latter sites.
In conclusion, cefotaxime appears to be an effective antimicrobial agent in treating gonococcal urethritis caused by f-lactamase-negative strains. Concomitant oral probenecid is not needed for cefotaxime efficacy in gonorrhea treatment.
